We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Chad Therapeutics, | AMEX:CTU | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
RNS Number:5872R Croftdene Limited 3 November 2003 FORM SAR 3 Date of disclosure..3 NOVEMBER 2003.... DISCLOSURE UNDER RULE 3 OF THE RULES GOVERNING SUBSTANTIAL ACQUISITIONS OF SHARES ("SARs") Date of acquisition......3 NOVEMBER 2003................. Acquisition in.....CONISTER TRUST PLC.........(name of company) (1) Class of voting shares Number of shares/rights If rights over shares (eg ordinary shares) over shares acquired acquired, as opposed to the shares themselves, specify nature of rights ...ORDINARY 25P.... ..68,637....shares ..................... ...N/A..........rights (2) Resultant total holding Resultant total holding Total percentage of voting shares (and % of rights over shares of total voting shares (and % of total voting in issue) shares in issue) ..6,7,34,230..( %) ...............( %) 27.04%...( %) (3) Party making disclosure....CROFTDENE LIMITED.................. (4) (a) Name of person acquiring shares or rights over shares CROFTDENE and, if different, beneficial owner......................LIMITED... (b) Names of any other persons acting by agreement or understanding (see SAR 5)............................ Signed, for and on behalf of the party named in (3) above................... (Also print name of signatory)........EVELYN CORRIN................ Telephone and extension number........01624 624364.................... Note. Under SAR 5, the holdings of and acquisitions by persons acting by agreement or understanding must be aggregated and treated as a holding of or acquisition by one person. Note 3 on SAR 5 requires persons who must aggregate holdings to disclose certain disposals. For full details of the SARs disclosure requirements, see Rules 3 and 5 of the SARs. If in doubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No: 020 7638 0129. This information is provided by RNS The company news service from the London Stock Exchange END SADGGMGMMFRGFZM
1 Year Chad Therapeutics Chart |
1 Month Chad Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions